Welcome to our dedicated page for Can-Fite BioPharma Ltd. SEC filings (Ticker: CANF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Can-Fite BioPharma Ltd. (CANF) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on the NYSE American. Can-Fite files an annual report on Form 20-F and frequent current reports on Form 6-K, which together describe its clinical programs, financial results, capital structure, and corporate actions. These filings are sourced in real time from the SEC’s EDGAR system and are organized for convenient review.
In its Form 6-K reports, Can-Fite often furnishes press releases covering developments such as clinical trial enrollment updates for Namodenoson in hepatocellular carcinoma, MASH, and pancreatic cancer; Phase III progress for Piclidenoson in psoriasis; and new data from compassionate use programs in advanced liver disease. Filings also document regulatory designations like Orphan Drug and Fast Track status, patent grants and notices of allowance, and information about veterinary and human licensing agreements.
CANF’s SEC reports additionally address corporate and financing matters, including public offerings, warrant amendments, reverse stock splits, ADS ratio changes, and shareholder meeting outcomes. Financial statements presented under U.S. GAAP outline revenues from licensing and distribution agreements, research and development expenses for its A3 adenosine receptor-targeted pipeline, and general and administrative costs.
On this page, users can review individual filings and use AI-powered summaries to quickly understand the key points of lengthy documents such as the Form 20-F and detailed Form 6-K exhibits. The platform also makes it easier to track how specific clinical, regulatory, and capital markets events are reflected across multiple filings over time.
Can-Fite BioPharma Ltd. files a Form F-3 resale registration to permit selling shareholders to resell up to 3,294,898 ordinary shares represented by 1,647,449 ADSs, consisting primarily of shares issuable upon exercise of repriced warrants.
The registration covers New Warrants and Placement Agent Warrants with an exercise price of $5.00 per ADS, exercisable for two years from the registration effective date; holders may exercise on a cashless basis under specified conditions. The company will not receive proceeds from resale transactions but may receive proceeds if warrants are exercised for cash (full cash exercise would yield approximately $8.01M). Shares outstanding were 4,285,093 ordinary shares as of March 30, 2026; pro forma outstanding assuming full warrant exercise is 7,579,991 ordinary shares.
Can-Fite BioPharma Ltd. files a post-effective amendment consolidating two prior Form F-1 registration statements to register resale of up to 67,879 ordinary shares represented by 33,940 ADSs. The prospectus covers (I) 9,546 ordinary shares (4,773 ADSs) from the January 2023 placement agent warrants and (II) 58,333 ordinary shares (29,167 ADSs) from the July 2025 placement agent warrants. Each ADS represents two ordinary shares after a January 5, 2026 ratio change. The company will not receive proceeds from resale by the selling shareholders; it may receive proceeds only if warrants are exercised for cash. Ordinary shares outstanding were 4,285,093 as of March 30, 2026.
Can-Fite BioPharma Ltd. filed a post-effective amendment to register resale of up to 67,879 ordinary shares represented by 33,940 ADSs. The registration aggregates (i) 9,546 ordinary shares (4,773 ADSs) from the January 2023 placement agent warrants and (ii) 58,333 ordinary shares (29,167 ADSs) from the July 2025 placement agent warrants. Each ADS represents two ordinary shares. The company will not receive proceeds from sales by the selling shareholders; however, it may receive proceeds if outstanding warrants are exercised for cash. Shares outstanding were 4,285,093 ordinary shares as of March 30, 2026.
Can-Fite BioPharma Ltd. reports that its veterinary partner Vetbiolix has completed enrollment in a randomized, double-blind, placebo-controlled Phase 2 study of Piclidenoson for osteoarthritis in 118 client-owned dogs. The 90-day, oral twice-daily trial focuses on mobility and pain reduction using validated scoring tools.
Vetbiolix funds all development and regulatory costs for registering Piclidenoson in companion animals and has exercised its option for a full licensing agreement. Can-Fite is eligible for upfront, milestone and royalty payments representing projected revenues of up to $325 million over the next decade, subject to successful development and commercialization. Top-line Phase 2 results are expected in Q3 2026.
Can-Fite BioPharma Ltd. is an advanced clinical-stage biopharmaceutical company developing orally available small molecules targeting the A3 adenosine receptor (A3AR) for cancer, liver and inflammatory diseases. Its ADSs trade on NYSE American under the symbol CANF, each ADS representing two ordinary shares.
The company has no approved products and has incurred recurring losses, with net losses of approximately $9.8 million in 2025, $7.9 million in 2024 and $7.6 million in 2023, leading to an accumulated deficit of about $176.2 million as of December 31, 2025. Cash and cash equivalents were $5.5 million and short-term deposits $3.0 million at that date, which management believes will fund operations for twelve months from the report’s issuance, but additional capital will be needed thereafter.
As of December 31, 2025, 2,618,425 ordinary shares were outstanding. On January 2, 2026, Can-Fite effected a 1‑for‑3,000 reverse split of its ordinary shares on the TASE and concurrently changed its ADS ratio to one ADS for two ordinary shares, effectively a one‑for‑twenty reverse ADS split. The filing details extensive risk factors, including clinical, regulatory, financing, competition, intellectual property and NYSE American continued-listing risks.
Can-Fite BioPharma reported 2025 results showing continued investment in its pipeline and a wider loss. Revenues were $0.41 million, down about 40% from $0.67 million in 2024, reflecting lower recognition of upfront distribution payments.
Research and development expenses rose to $6.69 million and general and administrative expenses to $3.66 million, driving a net loss of $9.83 million versus $7.88 million a year earlier. Cash, cash equivalents and short-term deposits totaled $8.54 million as of December 31, 2025, helped by financing activity, and the company received an additional $4.3 million from warrant exercises and an inducement in March 2026.
Clinically, a Phase 2a pancreatic cancer trial of Namodenoson met its primary safety endpoint, and more than 30% of heavily pretreated patients were alive at the latest cut-off. In hepatocellular carcinoma, one Namodenoson-treated patient has remained cancer-free for over nine years, while a Phase 3 HCC study and a Phase 2b trial in metabolic liver disease are ongoing. The company also highlighted a favorable case in decompensated cirrhosis, expansion into obesity indications, and new patents in several countries.
Can-Fite BioPharma Ltd. director Yoseph Bornstein filed an initial Form 3 reporting his holdings of stock options to purchase the company’s ordinary shares. The filing lists four option grants with different exercise prices, vesting schedules, and expiration dates.
One grant covers 200 underlying shares at an exercise price of $241.47, fully vested and expiring on June 22, 2031. Two additional grants each relate to 2,166 underlying shares, with exercise prices of $25.21 and $26.56 and expirations on April 30, 2033 and May 7, 2034, respectively; portions of these are already vested and the rest vest in specified quarterly installments. A larger grant covers 16,000 underlying shares at an exercise price of $2.18, expiring on January 25, 2030, with all of these options vesting in sixteen equal quarterly installments from April 25, 2026 through January 25, 2030.
The footnotes explain that, to qualify for certain Israeli tax benefits under Section 102, plan securities are held in the name of a trustee, and that the exercise prices were originally denominated in New Israeli Shekels and converted to U.S. dollars using a Bank of Israel exchange rate of 3.106 NIS per USD reported on March 11, 2026.
Can-Fite BioPharma director Abraham Sartani reported existing holdings of stock options to purchase Ordinary Shares. The Form 3 lists multiple option series with different exercise prices and expirations, showing his current derivative position rather than new market trades.
Examples include options over 16 shares at an exercise price of 2826.1400 per share expiring on November 8, 2027, and options over 2,166 shares at 25.2100 per share expiring on April 30, 2033. Another grant covers 16,000 shares at 2.1800 per share expiring on January 25, 2030.
Footnotes state that some grants are fully vested and exercisable, while others vest in scheduled quarterly installments between April 1, 2026 and January 25, 2030, contingent on Sartani’s continued service. Exercise prices were originally set in New Israeli Shekels and are presented here in U.S. dollars using a Bank of Israel exchange rate.
Can-Fite BioPharma Ltd. VP Business Development Sari Fishman filed an initial Form 3 showing holdings of multiple option grants to purchase Ordinary Shares. These options were granted between 2017 and 2025 with exercise prices originally set in New Israeli Shekels and translated into U.S. dollars.
Some option grants are already fully vested and exercisable, while others vest in scheduled quarterly installments between 2026 and 2029, contingent on continued service. To qualify for Israeli Section 102 tax benefits, the options are held in the name of a trustee.